EA201200823A1 - Гетероциклические производные сульфонамидов - Google Patents
Гетероциклические производные сульфонамидовInfo
- Publication number
- EA201200823A1 EA201200823A1 EA201200823A EA201200823A EA201200823A1 EA 201200823 A1 EA201200823 A1 EA 201200823A1 EA 201200823 A EA201200823 A EA 201200823A EA 201200823 A EA201200823 A EA 201200823A EA 201200823 A1 EA201200823 A1 EA 201200823A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- sulphonamides
- heterocyclic derivatives
- compounds
- inflammation
- cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Transplantation (AREA)
- AIDS & HIV (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
Abstract
В заявке описаны соединения формулы (I)и их фармацевтически приемлемые соли. Показано, что соединения являются ингибиторами MEK и поэтому их можно использовать для лечения гиперпролиферативных заболеваний (например, рака и воспаления).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN3019CH2009 | 2009-12-08 | ||
PCT/EP2010/069099 WO2011070030A1 (en) | 2009-12-08 | 2010-12-07 | Heterocyclic sulfonamide derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201200823A1 true EA201200823A1 (ru) | 2013-02-28 |
Family
ID=43708813
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201200823A EA201200823A1 (ru) | 2009-12-08 | 2010-12-07 | Гетероциклические производные сульфонамидов |
Country Status (26)
Country | Link |
---|---|
US (1) | US8614239B2 (ru) |
EP (1) | EP2509964B1 (ru) |
JP (1) | JP5456908B2 (ru) |
KR (1) | KR20120102750A (ru) |
CN (1) | CN102648188A (ru) |
AU (1) | AU2010329940B2 (ru) |
BR (1) | BR112012013735A2 (ru) |
CA (1) | CA2781218A1 (ru) |
CL (1) | CL2012001485A1 (ru) |
CO (1) | CO6551751A2 (ru) |
CR (1) | CR20120311A (ru) |
CU (1) | CU20120085A7 (ru) |
DO (1) | DOP2012000158A (ru) |
EA (1) | EA201200823A1 (ru) |
EC (1) | ECSP12011984A (ru) |
ES (1) | ES2484171T3 (ru) |
GE (1) | GEP20135998B (ru) |
GT (1) | GT201200183A (ru) |
IL (1) | IL219635A0 (ru) |
MA (1) | MA33848B1 (ru) |
MX (1) | MX2012006561A (ru) |
NI (1) | NI201200100A (ru) |
PE (1) | PE20121384A1 (ru) |
TN (1) | TN2012000242A1 (ru) |
WO (1) | WO2011070030A1 (ru) |
ZA (1) | ZA201203324B (ru) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103748085A (zh) | 2011-06-09 | 2014-04-23 | 诺华股份有限公司 | 杂环磺酰胺衍生物 |
JP2014517004A (ja) * | 2011-06-09 | 2014-07-17 | ノバルティス アーゲー | 複素環スルホンアミド誘導体 |
WO2013001372A2 (en) * | 2011-06-30 | 2013-01-03 | University Of Oslo | Methods and compositions for inhibition of activation of regulatory t cells |
CN103204825B (zh) | 2012-01-17 | 2015-03-04 | 上海科州药物研发有限公司 | 作为蛋白激酶抑制剂的苯并噻唑化合物及其制备方法和用途 |
WO2013130703A2 (en) * | 2012-02-29 | 2013-09-06 | Institute For Hepatitis And Virus Research | Binhibitors of hepatitis b virus convalently closed circular dna formation and their method of use |
US20190008859A1 (en) | 2015-08-21 | 2019-01-10 | Acerta Pharma B.V. | Therapeutic Combinations of a MEK Inhibitor and a BTK Inhibitor |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
GB1524747A (en) | 1976-05-11 | 1978-09-13 | Ici Ltd | Polypeptide |
ATE28864T1 (de) | 1982-07-23 | 1987-08-15 | Ici Plc | Amide-derivate. |
GB8327256D0 (en) | 1983-10-12 | 1983-11-16 | Ici Plc | Steroid derivatives |
US5093330A (en) | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
US5010099A (en) | 1989-08-11 | 1991-04-23 | Harbor Branch Oceanographic Institution, Inc. | Discodermolide compounds, compositions containing same and method of preparation and use |
US5395855A (en) | 1990-05-07 | 1995-03-07 | Ciba-Geigy Corporation | Hydrazones |
NZ243082A (en) | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
TW225528B (ru) | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
ATE348110T1 (de) | 1992-10-28 | 2007-01-15 | Genentech Inc | Hvegf rezeptor als vegf antagonist |
GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
PT817775E (pt) | 1995-03-30 | 2002-01-30 | Pfizer | Derivados de quinazolina |
GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
US5843901A (en) | 1995-06-07 | 1998-12-01 | Advanced Research & Technology Institute | LHRH antagonist peptides |
US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
PT836605E (pt) | 1995-07-06 | 2002-07-31 | Novartis Ag | Pirrolopirimidinas e processos para a sua preparacao |
US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
PL190489B1 (pl) | 1996-04-12 | 2005-12-30 | Warner Lambert Co | Nieodwracalne inhibitory kinaz tyrozyny, kompozycja farmaceutyczna je zawierająca i ich zastosowanie |
DE69734513T2 (de) | 1996-06-24 | 2006-07-27 | Pfizer Inc. | Phenylamino-substituierte tricyclische derivate zur behandlung hyperproliferativer krankheiten |
AU716610B2 (en) | 1996-08-30 | 2000-03-02 | Novartis Ag | Method for producing epothilones, and intermediate products obtained during the production process |
AU4141697A (en) | 1996-09-06 | 1998-03-26 | Obducat Ab | Method for anisotropic etching of structures in conducting materials |
DE19638745C2 (de) | 1996-09-11 | 2001-05-10 | Schering Ag | Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR) |
CA2265630A1 (en) | 1996-09-13 | 1998-03-19 | Gerald Mcmahon | Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders |
EP0837063A1 (en) | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazoline derivatives |
PT941227E (pt) | 1996-11-18 | 2004-08-31 | Biotechnolog Forschung Mbh Gbf | Epothilona d sua preparacao e sua utilizacao como agente citostatico ou como agente de proteccao fitossanitaria |
US6441186B1 (en) | 1996-12-13 | 2002-08-27 | The Scripps Research Institute | Epothilone analogs |
CO4950519A1 (es) | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
CO4940418A1 (es) | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
GB9721069D0 (en) | 1997-10-03 | 1997-12-03 | Pharmacia & Upjohn Spa | Polymeric derivatives of camptothecin |
US6194181B1 (en) | 1998-02-19 | 2001-02-27 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
MXPA00008365A (es) | 1998-02-25 | 2002-11-07 | Sloan Kettering Inst Cancer | Sintesis de epotilonas, intermediarios y analogos de las mismas. |
EP1107964B8 (en) | 1998-08-11 | 2010-04-07 | Novartis AG | Isoquinoline derivatives with angiogenesis inhibiting activity |
UA71587C2 (ru) | 1998-11-10 | 2004-12-15 | Шерінг Акцієнгезелльшафт | Translated By PlajАМИДЫ АНТРАНИЛОВОЙ КИСЛОТЫ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ЛЕЧЕБНЫХ СРЕДСТВ |
GB9824579D0 (en) | 1998-11-10 | 1999-01-06 | Novartis Ag | Organic compounds |
NZ511722A (en) | 1998-11-20 | 2004-05-28 | Kosan Biosciences Inc | Recombinant methods and materials for producing epothilone and epothilone derivatives |
DK1140173T4 (da) | 1998-12-22 | 2013-06-10 | Genentech Inc | Vaskulære endothelcellevækstfaktorantagonister og anvendelser deraf |
BR0009507A (pt) | 1999-03-30 | 2002-01-15 | Novartis Ag | Derivados de ftalazina para o tratamento de doenças inflamatórias |
PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
TWI238824B (en) | 2001-05-14 | 2005-09-01 | Novartis Ag | 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives |
GB0119249D0 (en) | 2001-08-07 | 2001-10-03 | Novartis Ag | Organic compounds |
EP1694663A1 (en) * | 2003-12-19 | 2006-08-30 | Biovitrum Aktiebolag | Novel benzofuran derivatives, which can be used in prophylaxis or treatment of 5-ht6 receptor-related disorder |
WO2008089459A1 (en) * | 2007-01-19 | 2008-07-24 | Ardea Biosciences, Inc. | Inhibitors of mek |
US20110098288A1 (en) * | 2008-03-11 | 2011-04-28 | Jeremy Major | Sulfonamides as zap-70 inhibitors |
-
2010
- 2010-12-07 US US13/514,208 patent/US8614239B2/en not_active Expired - Fee Related
- 2010-12-07 WO PCT/EP2010/069099 patent/WO2011070030A1/en active Application Filing
- 2010-12-07 EA EA201200823A patent/EA201200823A1/ru unknown
- 2010-12-07 BR BR112012013735A patent/BR112012013735A2/pt not_active IP Right Cessation
- 2010-12-07 EP EP10790407.0A patent/EP2509964B1/en not_active Not-in-force
- 2010-12-07 PE PE2012000778A patent/PE20121384A1/es not_active Application Discontinuation
- 2010-12-07 KR KR1020127017603A patent/KR20120102750A/ko active IP Right Grant
- 2010-12-07 JP JP2012542525A patent/JP5456908B2/ja not_active Expired - Fee Related
- 2010-12-07 CA CA2781218A patent/CA2781218A1/en not_active Abandoned
- 2010-12-07 AU AU2010329940A patent/AU2010329940B2/en not_active Ceased
- 2010-12-07 MX MX2012006561A patent/MX2012006561A/es not_active Application Discontinuation
- 2010-12-07 GE GEAP201012745A patent/GEP20135998B/en unknown
- 2010-12-07 CN CN2010800556652A patent/CN102648188A/zh active Pending
- 2010-12-07 ES ES10790407.0T patent/ES2484171T3/es active Active
-
2012
- 2012-05-07 ZA ZA2012/03324A patent/ZA201203324B/en unknown
- 2012-05-07 IL IL219635A patent/IL219635A0/en unknown
- 2012-05-21 TN TNP2012000242A patent/TN2012000242A1/en unknown
- 2012-05-31 CU CU2012000085A patent/CU20120085A7/es unknown
- 2012-06-06 CL CL2012001485A patent/CL2012001485A1/es unknown
- 2012-06-07 NI NI201200100A patent/NI201200100A/es unknown
- 2012-06-07 GT GT201200183A patent/GT201200183A/es unknown
- 2012-06-08 DO DO2012000158A patent/DOP2012000158A/es unknown
- 2012-06-08 CR CR20120311A patent/CR20120311A/es unknown
- 2012-06-12 CO CO12098541A patent/CO6551751A2/es not_active Application Discontinuation
- 2012-06-19 EC ECSP12011984 patent/ECSP12011984A/es unknown
- 2012-06-25 MA MA35003A patent/MA33848B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
US20120245209A1 (en) | 2012-09-27 |
MX2012006561A (es) | 2012-07-04 |
KR20120102750A (ko) | 2012-09-18 |
CU20120085A7 (es) | 2012-10-15 |
IL219635A0 (en) | 2012-07-31 |
GEP20135998B (en) | 2013-12-25 |
WO2011070030A1 (en) | 2011-06-16 |
CN102648188A (zh) | 2012-08-22 |
JP2013512941A (ja) | 2013-04-18 |
US8614239B2 (en) | 2013-12-24 |
CL2012001485A1 (es) | 2012-08-03 |
AU2010329940B2 (en) | 2013-05-16 |
NI201200100A (es) | 2012-08-13 |
EP2509964B1 (en) | 2014-04-30 |
CO6551751A2 (es) | 2012-10-31 |
ECSP12011984A (es) | 2012-07-31 |
GT201200183A (es) | 2014-03-27 |
CA2781218A1 (en) | 2011-06-16 |
MA33848B1 (fr) | 2012-12-03 |
DOP2012000158A (es) | 2012-09-30 |
ZA201203324B (en) | 2013-01-30 |
ES2484171T3 (es) | 2014-08-11 |
TN2012000242A1 (en) | 2013-12-12 |
AU2010329940A1 (en) | 2012-05-31 |
JP5456908B2 (ja) | 2014-04-02 |
CR20120311A (es) | 2012-10-04 |
EP2509964A1 (en) | 2012-10-17 |
PE20121384A1 (es) | 2012-10-13 |
BR112012013735A2 (pt) | 2019-09-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201200651A1 (ru) | Гетероциклические сульфонамидные производные, применимые в качестве ингибиторов мек | |
EA201300684A1 (ru) | Производные 6-амино-2-фениламино-1н-бензимидазол-5-карбоксамида и их применение в качестве ингибиторов микросомной простагландин-е2-синтазы-1 | |
EA201101533A1 (ru) | Гетероциклические соединения в качестве ингибиторов mek | |
UA111382C2 (uk) | Інгібітори протеїнкінази | |
PH12016500024A1 (en) | Bromodomain inhibitor | |
EA201200049A1 (ru) | 1,3-дизамещенные производные имидазолидин-2-она в качестве ингибиторов cyp 17 | |
EA201300730A1 (ru) | Производные индазолилтриазола | |
EA201390085A1 (ru) | Композиции ингибиторов киназ для лечения рака | |
EA201391720A1 (ru) | Замещенные диоксопиперидинилфталимидные производные | |
MX2014012695A (es) | Derivados de isoindolona. | |
EA201891553A1 (ru) | Ингибиторы syk | |
EA201400333A1 (ru) | Бензонитрильные производные в качестве ингибиторов киназ | |
EA201500278A1 (ru) | Пиразолилхиназолиновые ингибиторы киназы | |
MX352672B (es) | Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer. | |
EA201101583A1 (ru) | Ингибиторы pi3 киназы или mtor | |
EA201491671A1 (ru) | Гетероциклильные соединения | |
EA201291356A1 (ru) | Пиперидиноновые производные как ингибиторы mdm2 для лечения рака | |
GEP20156229B (en) | 5-alkynyl-pyrimidines | |
EA201290184A1 (ru) | Бензодиазепиновый ингибитор бромодомена | |
EA201591360A1 (ru) | Азабензимидазолы в качестве ингибиторов изозимов фдэ4 для лечения цнс и других расстройств | |
EA201170834A1 (ru) | Соединения, пригодные для ингибирования chk1 | |
EA201491247A1 (ru) | Производные дигидробензооксазина и дигидропиридооксазина | |
EA201490471A1 (ru) | Пиридазиноновые соединения и их применение в качестве ингибиторов daao | |
EA201592254A1 (ru) | Производные пиразолопирролидин-4-она и их применение при лечении заболевания | |
EA201200823A1 (ru) | Гетероциклические производные сульфонамидов |